Moreover, the expression level of Beclin-1 is also affected by different subtypes of breast cancer, with higher levels observed in more aggressive types such as human epidermal growth factor receptor type 2 (HER2) positive and basal-like (mostly triple-negative) breast cancers compared to the less malignant intraluminal A/B (luminal A/B) subtype [44]. Here, ERBB2 is linked to breast carcinoma.